Literature DB >> 29049133

HDL Cholesterol Efflux is Impaired in Older Patients with Early Sepsis: A Subanalysis of a Prospective Pilot Study.

Faheem W Guirgis1, Christiaan Leeuwenburgh2, Victor Grijalva3, Jennifer Bowman1, Colleen Kalynych1, Lyle Moldawer4, Frederick A Moore4, Srinivasa T Reddy3.   

Abstract

BACKGROUND: Proper functioning of high-density lipoprotein (HDL) is necessary for protection against sepsis. However, previous work has demonstrated that HDL becomes oxidized and dysfunctional (Dys-HDL) during sepsis. Older (aged >65 years) patients are at particularly high risk of sepsis and poor outcomes from sepsis. STUDY
OBJECTIVE: The aim of the study was to compare functional properties of HDL (cholesterol efflux capacity and paraoxonase enzyme 1 [PON-1] activity) and Dys-HDL between older (aged >65 years) sepsis patients and older healthy volunteers.
METHODS: This was a subanalysis of a prospective study in which patients with sepsis were prospectively enrolled from the emergency department within the first 24 h. Serum and plasma samples were drawn from septic patients and age- and sex-matched control subjects. Percent cholesterol efflux, HDL inflammatory index, and PON1 activity were measured. Data were analyzed using Student t test or Wilcoxon rank-sum test.
RESULTS: Ten sepsis and 10 healthy controls were analyzed. Mean age of sepsis patients (80 ± 2 years [SD]) and control subjects (77 ± 2 years) was similar (P = 0.31). Mean systolic blood pressures were significantly different in sepsis patients (113 ± 8 mmHg) compared with controls (133 ± 6 mmHg) (P = 0.049). Median SOFA scores for sepsis patients were 5.5 (interquartile range [IQR] 4-9). Mean percent cholesterol efflux was significantly reduced in sepsis (24.1 ± 1.2%) compared with controls (31.5 ± 1.0%) (P < 0.001). HDL inflammatory index was also significantly elevated in septic patients (1.63, IQR 1.3-2.34) compared with controls (0.62, IQR 0.56-0.67) (P < 0.001). However, PON1 activity was not significantly different between septic patients (70.3 ± 16.3 nmol/min/mL) and control subjects (88.8 ± 18.3 nmol/min/mL).
CONCLUSIONS: Cholesterol efflux capacity seems to be significantly impaired in sepsis patients who also exhibited a higher index of Dys-HDL. The findings suggest that HDL function may be impaired in older individuals with sepsis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29049133      PMCID: PMC5906212          DOI: 10.1097/SHK.0000000000001030

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  33 in total

1.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.

Authors:  Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

Review 2.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.

Authors:  M Navab; J A Berliner; G Subbanagounder; S Hama; A J Lusis; L W Castellani; S Reddy; D Shih; W Shi; A D Watson; B J Van Lenten; D Vora; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

Review 3.  Searching for a successful HDL-based treatment strategy.

Authors:  Srinivasa T Reddy; Mohamad Navab; G M Anantharamaiah; Alan M Fogelman
Journal:  Biochim Biophys Acta       Date:  2014-01

Review 4.  Pathogenetic mechanisms of septic shock.

Authors:  J E Parrillo
Journal:  N Engl J Med       Date:  1993-05-20       Impact factor: 91.245

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation.

Authors:  Andrew J Murphy; Kevin J Woollard; Andreas Suhartoyo; Roslynn A Stirzaker; James Shaw; Dmitri Sviridov; Jaye P F Chin-Dusting
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-07       Impact factor: 8.311

Review 7.  Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care.

Authors:  Lori F Gentile; Alex G Cuenca; Philip A Efron; Darwin Ang; Azra Bihorac; Bruce A McKinley; Lyle L Moldawer; Frederick A Moore
Journal:  J Trauma Acute Care Surg       Date:  2012-06       Impact factor: 3.313

8.  Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.

Authors:  R Phillip Dellinger; John F Tomayko; Derek C Angus; Steven Opal; Michael A Cupo; Sharon McDermott; Annie Ducher; Thierry Calandra; Jonathan Cohen
Journal:  Crit Care Med       Date:  2009-11       Impact factor: 7.598

9.  Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.

Authors:  Maureen McMahon; Jennifer Grossman; Brian Skaggs; John Fitzgerald; Lori Sahakian; Nagesh Ragavendra; Christina Charles-Schoeman; Karol Watson; Weng Kee Wong; Elizabeth Volkmann; Weiling Chen; Alan Gorn; George Karpouzas; Michael Weisman; Daniel J Wallace; Bevra H Hahn
Journal:  Arthritis Rheum       Date:  2009-08

10.  Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes.

Authors:  Cecilia Morgantini; Andrea Natali; Beatrice Boldrini; Satoshi Imaizumi; Mohamad Navab; Alan M Fogelman; Ele Ferrannini; Srinivasa T Reddy
Journal:  Diabetes       Date:  2011-08-18       Impact factor: 9.461

View more
  15 in total

1.  HDL and Sepsis.

Authors:  Huanhuan Cao; Wei Huang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Quantitative and Qualitative Assessments of Cholesterol Association With Bacterial Infection Type in Sepsis and Septic Shock.

Authors:  Lauren Page Black; Michael A Puskarich; Morgan Henson; Taylor Miller; Srinivasa T Reddy; Rosemarie Fernandez; Faheem W Guirgis
Journal:  J Intensive Care Med       Date:  2020-06-24       Impact factor: 2.889

3.  Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis.

Authors:  Narendra Kumar Sharma; Bianca Lima Ferreira; Alexandre Keiji Tashima; Milena Karina Colo Brunialti; Ricardo Jose Soares Torquato; Antonio Bafi; Murillo Assuncao; Luciano Cesar Pontes Azevedo; Reinaldo Salomao
Journal:  Clin Proteomics       Date:  2019-07-16       Impact factor: 3.988

4.  HDL inflammatory index correlates with and predicts severity of organ failure in patients with sepsis and septic shock.

Authors:  Faheem W Guirgis; Sunita Dodani; Christiaan Leeuwenburgh; Lyle Moldawer; Jennifer Bowman; Colleen Kalynych; Victor Grijalva; Srinivasa T Reddy; Alan E Jones; Frederick A Moore
Journal:  PLoS One       Date:  2018-09-14       Impact factor: 3.240

5.  LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P): Phase I/II clinical trial protocol of lipid emulsion therapy for stabilising cholesterol levels in sepsis and septic shock.

Authors:  Faheem W Guirgis; Lauren Page Black; Martin Daniel Rosenthal; Morgan Henson; Jason Ferreira; Christiaan Leeuwenburgh; Colleen Kalynych; Lyle L Moldawer; Taylor Miller; Lisa Jones; Marie Crandall; Srinivasa T Reddy; Samuel S Wu; Frederick A Moore
Journal:  BMJ Open       Date:  2019-09-18       Impact factor: 2.692

6.  Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice.

Authors:  Feng Su; Anantharamaiah Gm; Mayakonda N Palgunachari; C Roger White; Holly Stessman; Yanyuan Wu; Jay Vadgama; Richard Pietras; Dorothy Nguyen; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  J Cancer Res Ther Oncol       Date:  2020-01-17

Review 7.  High-density lipoproteins during sepsis: from bench to bedside.

Authors:  Sébastien Tanaka; David Couret; Alexy Tran-Dinh; Jacques Duranteau; Philippe Montravers; Anna Schwendeman; Olivier Meilhac
Journal:  Crit Care       Date:  2020-04-07       Impact factor: 9.097

8.  Arylesterase Activity of HDL Associated Paraoxonase as a Potential Prognostic Marker in Patients With Sepsis and Septic Shock-A Prospective Pilot Study.

Authors:  Alexander C Reisinger; Max Schuller; Michael Holzer; Julia T Stadler; Gerald Hackl; Florian Posch; Gunther Marsche; Harald Sourij; Robert Ekart; Kathrin Eller; Philipp Eller
Journal:  Front Med (Lausanne)       Date:  2020-10-22

9.  Prolonged bedrest reduces plasma high-density lipoprotein levels linked to markedly suppressed cholesterol efflux capacity.

Authors:  Athina Trakaki; Hubert Scharnagl; Markus Trieb; Michael Holzer; Helmut Hinghofer-Szalkay; Nandu Goswami; Gunther Marsche
Journal:  Sci Rep       Date:  2020-09-14       Impact factor: 4.379

10.  Lipid intensive drug therapy for sepsis pilot: A Bayesian phase I clinical trial.

Authors:  Faheem W Guirgis; Lauren Page Black; Elizabeth DeVos; Morgan Henson; Jason Ferreira; Taylor Miller; Martin Rosenthal; Christiaan Leeuwenburgh; Colleen Kalynych; Lyle Moldawer; Lisa Jones; Marie Crandall; Srinivasa T Reddy; Hanzhi Gao; Sam Wu; Frederick Moore
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.